RaQualia Pharma Inc. announced consolidated earnings results for the year ended December 31, 2020. For the full year, the company reported Net Sales were ¥1,107 million against ¥1,702 million a year ago. Operating loss was ¥486 million against ¥15 million a year ago. Loss attributable to owners of the parent was ¥606 million against profit attributable to owners of the parent of ¥5 million a year ago. Basic loss per share was ¥28.97 against basic earnings per share of ¥0.26 a year ago.